| Drug Name |
Rabeprazole |
| Drug ID |
BADD_D01898 |
| Description |
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. |
| Indications and Usage |
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use. |
| Marketing Status |
approved; investigational |
| ATC Code |
A02BC04 |
| DrugBank ID |
DB01129
|
| KEGG ID |
D08463
|
| MeSH ID |
D064750
|
| PubChem ID |
5029
|
| TTD Drug ID |
D0KL4J
|
| NDC Product Code |
65162-724 |
| UNII |
32828355LL
|
| Synonyms |
Rabeprazole | 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole | Dexrabeprazole | E 3810 | E3810 | Pariet | Rabeprazole Sodium | Sodium, Rabeprazole | 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt | Aciphex | LY-307640 | LY 307640 | LY307640 |
